New Delhi, India

Sarkar Arindam

This inventor holds 1 USPTO granted patent. Top assignee: Akamara Therapeutics, Inc.. Active years: 2020.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Spotlight: Sarkar Arindam from New Delhi

Introduction

Sarkar Arindam is a prominent inventor based in New Delhi, India. With a focus on pharmaceutical and chemical sciences, he has made significant contributions to the field through his innovative work on platinum-based compounds.

Latest Patents

Sarkar holds one patent for his invention titled "Crystalline platinum-based compounds." The patent details a crystalline platinum-based compound known as IO-125, along with compositions and formulations comprising this compound. It also provides insights into the methods of preparing this crystalline compound and its potential uses in pharmaceutical applications.

Career Highlights

Currently, Sarkar Arindam is affiliated with Akamara Therapeutics, Inc., where he continues to advance his research. His work at the company highlights his commitment to developing new therapeutic solutions that leverage the unique properties of platinum-based compounds.

Collaborations

In his professional journey, Sarkar collaborates with talented individuals such as Gavin Pringle and Jonathan James Loughrey. These partnerships exemplify the collaborative spirit of innovation that drives advancements in the field of drug development.

Conclusion

Sarkar Arindam stands out as a dedicated inventor in the realm of pharmaceutical sciences. His patent for crystalline platinum-based compounds underscores his role in contributing to innovative solutions in healthcare. As he continues his work at Akamara Therapeutics, the impact of his inventions is poised to benefit the medical community and improve patient outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…